Back to Search Start Over

329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib

Authors :
J.W. Riess
J.A. De Langen
Z. Piotrowska
S.B. Goldberg
J.W. Goldman
I. Okamoto
S. Ponce Aix
S. Teraoka
H. Ambrose
K.H. Tang
J. Maidment
B. Merchan Ruiz
N. Hewson
J. Cosaert
H.A. Yu
Source :
Annals of Oncology. 33:S1571-S1572
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Subjects

Subjects :
Oncology
Hematology

Details

ISSN :
09237534
Volume :
33
Database :
OpenAIRE
Journal :
Annals of Oncology
Accession number :
edsair.doi...........b6c5c41887404959ad8797251cee0a1d